Schizophrenia
Eli Lilly's Zyprexa Will Remain the Clinical Gold Standard for the Treatment of Schizophrenia Through 2015
Published in Drug Week, March 16th, 2007
Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Eli Lilly's Zyprexa will remain the gold standard for the treatment of schizophrenia through 2015. According to a new report entitled Schizophrenia: Turning Physician Insight into Projected Patient Share, Zyprexa is superior in efficacy to all other current therapies, particularly on measures that are most important to prescribers, such as impact on global symptoms and responder rate.
In spite of scoring* less favorable than the other drugs in terms of safety and lower than risperidone in terms of delivery features, Zyprexa is the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2007-03-16)
More Articles from Drug Week
- Addiction Medicine
Antidepressants help men decrease alcohol consumption, but not women - Barrett's Esophagus
NSAIDs modulate biomarker panel for esophageal adenocarcinoma - Cataracts
AAO Reminds Patients Taking Prostate Meds to Inform Doctor before Cataract Surgery - Collaborations
Takeda and Tap to promote Sucampo's Amitiza in the United States - Drug Development
Manchester physicists pioneer new super-thin technology - Drug Development
Study of atomic movement may influence design of pharmaceuticals - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
